Charity registration number: 1189246

Brit-PACT
British Psoriatic Arthritis ConsorTium

BRITISH PSORIATIC ARTHRITIS CONSORTIUM
TRUSTEES' REPORT AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

D.R. Hicks
CHARTERED ACCOUNTANTS

British Psoriatic Arthritis Consortium
Contents

	Page
Trustees' Report	1—4
Independent Examiner's Report	5
Statement of Financial Activities	6
Comparative Statement of Financial Activities	7
Statement of Financial Position	8
Notes to the Financial Statements	9—12
The following pages do not form part of the statutory accounts:	
Detailed Statement of Financial Activities	13

British Psoriatic Arthritis Consortium
Trustees' Report For The Year Ended 31 March 2026

The trustees present their report and the financial statements for the year ended 31 March 2026.

Objectives and Activities

Aims and Objectives

"The object of the CIO is to relieve sickness and to preserve and protect good health for the public benefit by promoting medical knowledge, and excellence through education and research with particular reference to the diseases of psoriasis and psoriatic arthritis."

Public Benefit

In this financial year, Brit-PACT continued to progress with its mission to support education and research into psoriatic arthritis (PsA) in the UK.

We held another successful Annual Meeting in the hybrid format at the BCEC, Birmingham, on 10th October 2025 and it was organised and chaired by Prof Pauline Ho, Dr Muhamad Jasim and Dr Ashley Elliot. 39 delegates attended the meeting in person while another 24 attendees joined in online. The meeting highlights included a presentation by Dr Andrea Di Matteo about the use of ultrasound in psoriatic disease and how that can help guide treatment decisions. We also had a debate on the topic 'The use of dual biologic therapy in PsA: Is this required?' with Prof Bruce Kirkham speaking for the motion and Dr William Tillett arguing against the motion. Mr Andy Kelly provided an update on behalf of the Brit-PACT Patient Partners and that was followed by an online case presentation and discussion about the use of dual biologics by Prof Helena Marzo-Ortega. There were also presentations from Brit-PACT Researcher and Clinician Abstract Prize Winners and Runners up as well as updates regarding the various Brit-PACT funded research projects. Excellent feedback was received for the meeting with 93% of the attendees rating the meeting 'highly relevant' to their educational needs while a further 4% felt that the meeting was 'mostly relevant' regarding this objective.

Moreover, in November 2025 we also had the Spondyloarthritis Golden Anniversary Meeting in Leeds. The purpose of it was to celebrate and review the five decades of scientific discovery, clinical progress, and collaborative partnerships since the first publication on the spondyloarthritis (SpA) concept 50 years ago. The meeting was jointly arranged by us and Brit-SpA, our sister organisation which focuses on axial spondyloarthritis, and was chaired by Professors Philip Helliwell and Helena Marzo-Ortega. This was a 2-day event with 100 attendees and it began on Thursday 27th November evening with a warm and engaging Celebration Dinner. Prof Helliwell and Prof Marzo Ortega opened the evening with welcoming remarks and reflections on the history of the SpA concept. This was followed by an excellent talk from Prof Iain McInnes, who explored how our understanding of SpA pathophysiology has evolved dramatically over the last 50 years, and what the future might hold for us. The anniversary meeting on Friday 28th November had presentations from an outstanding line up of national and international experts, each highlighting key milestones and emerging directions in SpA research. The presentations covered the evolution of classification criteria, advances in imaging, the role of animal models in shaping scientific understanding, and major developments in genetics. Further sessions focused on axial and peripheral disease, the importance of recognising skin involvement, and the transformation of treatment strategies over time. The meeting concluded with forward-looking discussions on future initiatives and research opportunities, offering an exciting glimpse of what lies ahead. By bringing together pioneers who shaped the field and innovators who are driving it forward, the Golden Anniversary Meeting proved to be a memorable celebration of progress and an inspiring foundation for the next chapter in SpA research. Unsurprisingly, excellent feedback was received for this meeting too with 95% of the attendees rating the meeting 'highly relevant' to their educational needs while a further 5% felt that the meeting was 'mostly relevant' regarding this objective.

The Brit-PACT pilot research grant scheme continues as before and the award for this is now in memory of Dr Deepak Jadon, a valued member of the Brit-PACT steering committee, who sadly died in 2023. All grants submitted were asked to include at least one of the 'Top 10' items identified in the James Lind Priority Setting Partnership, which had been funded and published previously by Brit-PACT. The applicants were also asked to address an issue of importance and relevance to psoriatic disease and in line with the aims and purposes of Brit-PACT. Four high quality applications were received and one research grant of £15,000 was awarded to a researcher at the University of Manchester.

We have also continued to support other research with external funding. The SEQUENCE project, a multicentre observational study that was launched in 2022 to understand inequity of biologics prescribing across the UK and had high engagement from the general Brit-PACT membership, has now been completed. Updates on this study were provided by Dr Charlotte Gollins at the annual meeting in October 2025 and articles based on it have been published in Rheumatology, the flagship journal of the British Society for Rheumatology. The White Swan project involved using social media data to understand the lived experience of people with psoriatic arthritis receiving biologic therapies and weight management interventions. An update about this project was also presented by Dr James Kimpton at the annual meeting in October 2025 and an abstract based on the findings was presented as a poster at the BSR (British Society for Rheumatology) annual conference in April 2026.

Brit-PACT continues to provide support and updates to the British Society for Rheumatology on its activities and provides support to subcommittees of the BSR such as recommendations for biologic use in psoriatic arthritis.

The trustees confirm that they have complied with the requirements of Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit.

Achievements and Performance

Main Achievements

1. Psoriatic Arthritis Education for Health Care Professionals

Brit-PACT continues to conduct educational meetings for rheumatology health care professionals and seeks to grow membership with a wider spectrum of HCPs, including dermatologists and allied health professionals. Our main educational events this year were the Annual meeting in October 2025 and the Spondyloarthritis Golden Anniversary Meeting in November 2025. An update on behalf of the Charity was also presented as part of the Spondyloarthritis Special Interest Group at the British Society for Rheumatology Annual Conference in April 2026.

2. Funding and supporting Psoriatic Arthritis Research

During 2025 Brit-PACT has funded one research project which aims to answer research questions relevant to patients with PsA. This year's Deepak Jadon Pilot Research Grant was awarded to Dr Stephanie Shoop-Worrall (University of Manchester) for the project titled 'The Obesity Conundrum: Childhood obesity and time to diagnosis and early outcome in Juvenile psoriatic Arthritis' and she presented a project update to the Brit-PACT membership at the Annual meeting in October 2025. A project update was also presented at this meeting by Dr Steven Zhao (University of Manchester) who had been awarded a pilot research grant in 2024 for his project titled 'Blood Biomarker for Timely Diagnosis of Psoriatic Arthritis'.

3. Sharing patient perspective on living with psoriatic disease.

The patient partners continue to share the patient perspective with clinicians and other healthcare professionals and collaborate with various organisations to inform research direction. One of the patient members of the Steering Committee presented at the Annual Meeting. The patient group has also advised on Psoriatic Arthritis consensus recommendations and engaged with various activities including surveys, workshops and assisting with grant applications and other engagement/ involvement opportunities.

Financial Review

Reserves Policy

The board of trustees agree to run the charity with reserves sufficient to meet expenses for approximately one year.

Structure, Governance and Management

Governing Document

The charity is constituted as a Charitable Incorporated Organisation (CIO) in England & Wales. The governing document of the charity is the constitution of the CIO as approved by the Charity Commission in England & Wales (CCEW) .
The governing document is dated 20 April 2020.
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.
The trustees are all individuals.

Trustee Selection Methods

The Brit-PACT constitution incorporates elections for major executive committee positions. The Executive Committee (trustees) includes rheumatologists (both consultants and trainees), allied health professionals and patient partners. In line with the constitution of the Charity nominations are sought annually for new executive committee members as vacancies become available. Voting is by a single vote of all members and the majority vote is taken as the definitive result. In this calendar year there have been one retirement from the executive committee (Ms Clare Allen), two members were re-elected for a second term (Prof Pauline Ho and Dr Tania Gudu) and one new medical member elected (Dr Carmel Stober). Dr Willliam Tillet was also elected as Chair of Brit-PACT and he took over this role from Dr Nicola Gullick.

Reference and Administrative Details

Trustees

L Coats (resigned 10/10/2025)
N Gullick
P Helliwell
T Gudu
C Allen (resigned 10/10/2025)
P Ho
A Kelly
S Mukherjee
R Hum
J Bluett
C Stober (appointed 10/10/2025)
W Tillett
M Jasim
A Elliot
J Packham
J Begham

Charity Number

1189246

Principal Address

Department 1, Wolfson Building
Royal United Hospital
Bath
BA1 3NG

Independent Examiner

DR Hicks Chartered Accountants
DR Hicks
Chartered Accountants
107 Penn Hill Road
Bath
BA1 3RU

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing the financial statements the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgments and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping adequate accounting records which disclose with reasonable accuracy at anytime the financial position of the charity and to enable them to ensure that the accounts comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The trustees' report was approved by the board of trustees and signed on its behalf by:

Sandeep Mukherjee

S Mukherjee

Trustee
16/10/2026

British Psoriatic Arthritis Consortium
Independent Examiner's Report to the Trustees of British Psoriatic Arthritis Consortium
For The Year Ended 31 March 2026

I report to the trustees on my examination of the accounts of British Psoriatic Arthritis Consortium (the Trust) for the year ended 31 March 2026.

Responsibilities and Basis of Report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and contents of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

DR Hicks

DR Hicks Chartered Accountants

04/08/2026
107 Penn Hill Road
Bath
BA1 3RU

British Psoriatic Arthritis Consortium
Statement of Financial Activities
For The Year Ended 31 March 2026

	Notes	Unrestricted funds £	Restricted funds £	2026 Total funds £	2025 Total funds £
INCOME AND ENDOWMENTS FROM:					
Donations and legacies	**3**	213	-	213	142
Other trading activities	**4**	60,000	-	60,000	25,000
Investments	**5**	308	-	308	246
		60,521	-	60,521	25,388
EXPENDITURE ON:					
Raising funds	**6**	(70,077)	-	(70,077)	(65,815)
NET EXPENDITURE		(9,556)	-	(9,556)	(40,427)
NET MOVEMENT IN FUNDS		(9,556)	-	(9,556)	(40,427)
RECONCILIATION OF FUNDS:					
Total funds brought forward		79,272	52,648	131,920	172,347
TOTAL FUNDS CARRIED FORWARD	**11**	69,716	52,648	122,364	131,920

The notes on pages 9 to 12 form part of these financial statements.

British Psoriatic Arthritis Consortium
Comparative Statement of Financial Activities
For The Year Ended 31 March 2026

	Notes	Unrestricted funds	Restricted funds	2025 Total funds
		£	£	£
INCOME AND ENDOWMENTS FROM:				
Donations and legacies	3	142	-	142
Other trading activities	4	25,000	-	25,000
Investments	5	246	-	246
		25,388	-	25,388
EXPENDITURE ON:				
Raising funds	6	(58,765)	(7,050)	(65,815)
NET EXPENDITURE		(33,377)	(7,050)	(40,427)
NET MOVEMENT IN FUNDS		(33,377)	(7,050)	(40,427)
RECONCILIATION OF FUNDS:				
Total funds brought forward		112,649	59,698	172,347
TOTAL FUNDS CARRIED FORWARD	11	79,272	52,648	131,920

The notes on pages 9 to 12 form part of these financial statements.

British Psoriatic Arthritis Consortium
Statement of Financial Position
As At 31 March 2026

	Notes	Unrestricted funds	Restricted funds	2026 Total funds	2025 Total funds
		£	£	£	£
CURRENT ASSETS					
Debtors	9	1,985	-	1,985	5,713
Cash at bank and in hand		123,541	-	123,541	128,688
		125,526	-	125,526	134,401
Creditors: Amounts Falling Due Within One Year	10	(3,162)	-	(3,162)	(2,481)
NET CURRENT ASSETS (LIABILITIES)		122,364	-	122,364	131,920
TOTAL ASSETS LESS CURRENT LIABILITIES		122,364	-	122,364	131,920
NET ASSETS		122,364	-	122,364	131,920
FUNDS OF THE CHARITY					
Restricted Funds				52,648	52,648
Unrestricted Funds				69,716	79,272
TOTAL FUNDS	11			122,364	131,920

On behalf of the board

Sandeep Mukherjee

S Mukherjee

Trustee
16/10/2026

The notes on pages 9 to 12 form part of these financial statements.

1. General Information

British Psoriatic Arthritis Consortium is a charitable incorporated organisation registered with the Charity Commission, registered charity number 1189246. The principal address is Department 1, Wolfson Building, Royal United Hospital, Bath, BA1 3NG.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)", Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities Act 2011.

The charity is a Public Benefit Entity as defined by FRS 102.

2.2. Going Concern Disclosure

The trustees have not identified any material uncertainties related to events or conditions that may cast significant doubt about the charity's ability to continue as a going concern.

2.3. Incoming Resources

Nature of income
Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income
Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.
Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.
Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.
Income recognition
"Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs."

2.4. Resources Expended

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..
Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

2.5. **Cash and Cash Equivalents**

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

3. **Income from Donations and Legacies**

	2026 Unrestricted funds	2025 Unrestricted funds
	£	£
Donations and gifts	213	142

4. **Income from Other Trading Activities**

	2026 Unrestricted funds	2025 Unrestricted funds
	£	£
Sponsorships	60,000	25,000

5. **Investment Income**

	2026 Unrestricted funds	2025 Unrestricted funds
	£	£
Bank interest receivable	308	246

6. **Analysis of Expenditure**

	Activities undertaken directly	Grant funding of activities	Support costs (see note 7)	2026 Total
	£	£	£	£
Raising funds	37,803	25,000	7,274	70,077

	Activities undertaken directly	Grant funding of activities	Support costs (see note 7)	2025 Total
	£	£	£	£
Raising funds	33,805	25,000	7,010	65,815

7. Support Costs

	2026 Raising funds	2025 Raising funds
	£	£
Employee costs	1,014	947
Premises expenses	1,850	1,850
General administration	4,410	4,213
	7,274	7,010

8. Independent Examiner's Remuneration

	2026	2025
	£	£
Independent examination of the financial statements	1,438	1,398

9. Debtors

	2026	2025
	£	£
Due within one year		
Other debtors	1,985	5,713

10. Creditors: Amounts Falling Due Within One Year

	2026	2025
	£	£
Trade creditors	3,162	2,481

11. Movement in Funds

	As at 1 April 2025	Income	Expenditure	As at 31 March 2026
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	79,272	60,521	(70,077)	69,716
Restricted funds				
Sequence Project	52,648	-	-	52,648
Total funds	131,920	60,521	(70,077)	122,364

	As at 1 April 2024	Income	Expenditure	As at 31 March 2025
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	112,649	25,388	(58,765)	79,272

...CONTINUED

Restricted funds				
Sequence Project	59,698	-	(7,050)	52,648
Total funds	172,347	25,388	(65,815)	131,920

12. **Related Party Disclosures**

There have been no related party transcations in the reporting period that require discolsure.

British Psoriatic Arthritis Consortium
Detailed Statement of Financial Activities
For The Year Ended 31 March 2026

	2026 Total funds £	2025 Total funds £
INCOME AND ENDOWMENTS FROM:		
Donations and legacies		
Donations from individuals	213	142
	213	142
Other trading activities		
Sponsorships	60,000	25,000
	60,000	25,000
Investments		
Bank interest receivable	308	246
	308	246
	60,521	25,388
EXPENDITURE ON:		
Raising funds		
Administration fees	(5,907)	(4,561)
Abstract Award	(680)	(500)
Patient Partner expenses	(105)	(510)
Course expenses	(10,040)	(9,064)
Project expenses	-	(19,170)
50th Anniversiary Meeting	(21,071)	-
Grants to institutions	(25,000)	(25,000)
Travel and subsistence expenses	(1,014)	(947)
Rent	(1,850)	(1,850)
Computer software, consumables and maintenance	(924)	(728)
Insurance	(368)	(368)
Printing, postage and stationery	(91)	(299)
Telecommunications and data costs	(237)	(200)
Independent examiner's fees	(1,438)	(1,398)
Subscriptions	(275)	(220)
Bookkeeping fees	(960)	(930)
Bank charges	(117)	(70)
	(70,077)	(65,815)
	(70,077)	(65,815)
NET EXPENDITURE	(9,556)	(40,427)